estimated, but it appears that this event may be substantially more frequent with a cord blood source of stem cells. There are several potential explanations for leukemogenesis via this unusual route. [1] [2] [3] [4] Perhaps, the most plausible was predicted for cord blood before the recent series of case reports. 5, 6 Systematic screening of a large series of unselected cord blood samples revealed that B1% harboured putative pre-leukaemic clones with TEL-AML1 fusion or B0.2% with AML-ETO. 5 The frequency of such cells in positive cord bloods was of the order of 10 À3 -10 À4 , indicative of a clone size of B10 6 cells in the new born. It was suggested that the clinical use of such 'preleukaemic' samples as a source of stem cells might involve a risk of leukaemia in association with the proliferative stress consequent to transplantation. 5 Several inferences can be drawn from the data. First, if results with these particular fusion genes are typical of prenatal leukemia initiation in general, 7 then something like 5% of cord bloods may contain pre-leukemic clones. Second, the risk of the cord blood donor with such clones developing leukaemia him or herself is very low and of the order of 1%.
These conclusions have implications for how one should respond to the cases of donor 'relapse'. The priority must be to establish the mechanism of donor cell leukaemia. If the above mechanism is at play, then the clear prediction is that cells bearing at least one of the molecular abnormalities found in the 'relapse' leukaemic blasts (i.e. the initiating mutation) would be present and detectable in archived donor cells. This would need to be assessed by carefully controlled reverse transcriptasepolymerase chain reaction plus combined immunophenotypefluorescence in situ hybridization technologies as described. 5 If this turns out to be the case, then there are other issues to be addressed, including additional ethical concerns. 8 Given the B1% risk of leukaemia in the donor, one would not expect to see leukaemia emerging in that individual and one can argue that it would be unethical to inform the donor or the donor's parents. Screening all cord bloods for potential 'contamination' with pre-leukaemic clones might be desirable, but would not be very practical given the wide variety of chromosomal and mutational events that could initiate acute leukaemia. Cord blood transplantation has been a very considerable success 9 and it is unlikely that donor cell leukaemia would seriously compromise its continued use. Nevertheless, there is now some urgency to establish the frequency of donor cell leukaemia by more systematic screening of 'relapse' cases in the EUROCORD project and elsewhere and identifying whether or not this does indeed reflect transfer of pre-leukaemic clones. The genetic basis of this disorder is poorly understood. Cytogenetic abnormalities differ from those commonly reported in other B-cell neoplasms. Translocations involving immunoglobulin heavy-chain gene (IgH) are a common genetic change in multiple myeloma (MM) (75%) and a recurrent abnormality in many B-cell lymphomas such as t(11;14)(q123;q32) in mantle cell lymphoma, t(14;18)(q32;q21) in follicular lymphoma and t(9;14)(p13;q32) in lymphoplasmocytic lymphoma. On the other hand, the incidence of IgH rearrangements is low in WM (o3%).
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1,2 The translocation t(11;18)(q21;q21), a specific abnormality, observed in about 20% of extranodal marginal zone lymphomas has been reported in few cases of patients with WM. 3, 4 However, this translocation was not detected in the tumor cells of 24 WM patients using well-validated probe for its detection. 1 Deletions of chromosome 13q14 are present in approximately 50% of patients with MM or B-cell chronic lymphocytic leukemia (B-CLL), but are rare in WM at the time of diagnosis (o5%) and with a low frequency in patients after treatment (15%). 5 The deletion of the long arm of chromosome 6 is a recurrent abnormality reported in about 50%, in cases of WM mainly in advanced disease and is frequently associated with clonal evolutions ( With the exception of one patient with monosomy 9, no aneuploid cell populations were detected in tumor cells from 15 patients with WM by interphase fluorescent in situ hybridization (FISH) using centromeric probes for chromosomes frequently found to be aneuploid in MM and B-CLL (7, 9, 11, 12, 15 and 17).
1 Nevertheless, some sporadic karyotype aberrations consistent with aneuploidy have been reported in the literature and the set of probes precedently enumered can miss an aneupolidy, like trisomy 4 reported as the sole abnormality in one case of WM patient. 6 We analyzed by conventional cytogenetic (CC) a cohort of 39 patients with a diagnosis of WM, according to the Workshop classification (at diagnosis in 23 patients and after a median evolution of 3.8 years in 13). The observation of three patients with trisomy 4 detected by CC prompted us to search additional cases of this abnormality, by interphase FISH (IP-FISH) using a centromeric probe from chromosome 4. The results of the karyotypes and IP-FISH are detailed in Table 1 . In our study, among 37 patients with evaluable metaphases and 13 with abnormalities, none had a deletion or rearrangement of 6q and one harbored a t(11;18)(q21;q21) (No. 19). However, we found three patients with a whole trisomy 4 (8%) (Nos. 4, 24 and 33) and one with a partial trisomy 4 (No. 29). Trisomy 4 was the sole abnormality in two patients (Nos. 4 and 24) and was associated with trisomy 18 and the gain of a marker chromosome in the third. Metaphase cytogenetic studies in WM are hampered by the low proliferative activity of the lymphoplasmocytic cells as in the MM or monoclonal gammapathies. In the larger studies published yet, detection of chromosomal abnormalities was weak with CCs. Louviaux et al. Blood 1998; 92: 184b; abstract reported only 12 patients out of 45 with chromosomal abnormalities (27%), and Schop et al. 13 patients among 35 (37%). These results are comparable with our finding of 13 patients with abnormalities among 37 (35%).
FISH on interphase cells has greatly improved the detection of chromosomal abnormalities as it is independent of cells proliferative capacity. Thus, we decided to search for additional cases with trisomy 4 by IP-FISH on cytogenetic cryopreserved pellets in our cohort of 39 patients. To our knowledge, chromosomal aneuploidy was never screened with centromeric probe (CEP) probe for chromosome 4 in WM. The three complete trisomies 4, already seen by CC, were confirmed. As Trisomy 4 was the sole abnormality in two of the three karyotypes where it was identified and in one sporadic case reported previously. Thus, trisomy 4 could be a specific primary genetic event in WM. Moreover, the detection of one partial trisomy 4 defined an interesting region with coding genes for oncogenes. One of them, the c-KIT gene, is located on chromosome 4q12 and is expressed in about half of the CD34 þ precursors and mast cells. Activating mutations of c-KIT are found in mast cell disease but also in acute myeloid leukemia (AML), preferentially in core binding factor AML. In bone marrow biopsies of WM patients, an excess of mast cells have been found. It was shown that the expression of CD40 ligand on bone marrow mast cells supports the growth of lymphoplamocytic cells in patients with WM. We decided to look for c-KIT gene abnormalities in our patients with trisomy 4. Molecular analysis was performed in three patients. Coding sequence from exons 8 to 13 and 17, the most frequently mutated, were sequenced. A Val for Met substitution at codon 541 was identified in one patient only at the RNA level. This variant has been already reported in other tissues and tumors, but little is known about its significance. On the one hand, some authors considered this variation as a polymorphism identified in 1.5-9% of healthy subjects. On the other hand, there are accumulating elements suggesting an impact in human pathology. First, the Met541Leu variant was significantly more frequent in normal tissues of CML patients than of healthy subjects (8.8 vs 1.5%). In addition, this variant was found as an authentic somatic event that occurred in CML cells from one patient during blastic crisis, whereas it was not detected in chronic phase. Second, it was recently observed in seven out of seven dedifferentiated and three out of seven well-differentiated liposarcoma. Third, P Dubreuil et al. (unpublished results) recently identified this variant at the RNA level in pathological skin biopsies of 31 of 169 mastocytosis patients (18.3%), and in the genomic DNA of only 1/71 (1.5%) healthy subjects (Po0.005). Interestingly, genomic DNA sequencing of normal blood cells in 10 patients with Met541Leu variant identified in pathological tissues did not reveal any allelic variation,
